Ligan Pharmaceuticals spends approximately $740 million to acquire Zoma Corporation

Ligan Pharmaceuticals announced that it has reached an agreement to acquire Zoma Licensing, a biotech licensing investment company, for approximately $740 million.
Under the terms of the agreement, Ligan will purchase Zoma’s stock at a cash price of $39 per share, a 2.9% premium over its closing price of $37.90 last Friday.
The transaction is expected to be completed in the third quarter of this year. (Sina Finance)

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin